Sylvia MC Vijgen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sylvia MC Vijgen has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Maria Gabriel Van Pampus
OLVG Department Obstetrics and Gynecology
2 shared publications A Franx
Sint Elisabeth Hospital, Tilburg, the Netherlands
1 shared publicationA Kwee
University Medical Centre, Utrecht, The Netherlands
1 shared publicationA Lub
Spaarne Hospital, Hoofddorp, The Netherlands
1 shared publicationAP Drogtrop
Twee steden Hospital, Tilburg, The Netherlands
1 shared publicationAj van Loon
Martini Hospital, Groningen, the Netherlands
1 shared publication
Latest Publications
- 14 September 2010
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 117 (13) , 1577-1585
An economic analysis of induction of labour and expectant monitoring in women with gestational hypertension or pre‐eclampsia at term (HYPITAT trial)
Please cite this paper as:Vijgen S, Koopmans C, Opmeer B, Groen H, Bijlenga D, Aarnoudse J, Bekedam D, van den Berg P, de Boer K, Burggraaff J, Bloemenkamp K, Drogtrop A, Franx A, de Groot C, Huisjes A, Kwee A, van Loon A, Lub A, Papatsonis D, van der Post J, Roumen F, Scheepers H, Stigter R, Willekes C, Mol B, Van Pampus M for the HYPITAT study group. An economic analysis of induction of labour and expectant monitoring in women with gestational hypertension or pre‐eclampsia at term (HYPITAT trial). BJOG 2010;117:1577–1585.Objective To assess the economic consequences of labour induction compared with expectant monitoring in women with gestational hypertension or pre‐eclampsia at term.Design An economic analysis alongside the Hypertension and Pre‐eclampsia Intervention Trial At Term (HYPITAT).Setting Obstetric departments of six university and 32 teaching and district hospitals in the Netherlands.Population Women diagnosed with gestational hypertension or pre‐eclampsia between 36+0and 41+0 weeks of gestation, randomly allocated to either induction of labour or expectant monitoring.Methods A trial‐based cost‐effectiveness analysis was performed from a societal perspective during a 1‐year time horizon.Main outcome measures One‐year costs were estimated and health outcomes were expressed as the prevalence of poor maternal outcome defined as either maternal complications or progression to severe disease.Results The average costs of induction of labour (n = 377) were €7077 versus €7908 for expectant monitoring (n = 379), with an average difference of −€831 (95% CI −€1561 to −€144). This 11% difference predominantly originated from the antepartum period: per woman costs were €1259 for induction versus €2700 for expectant monitoring. During delivery, more costs were generated following induction (€2190) compared with expectant monitoring (€1210). No substantial differences were found in the postpartum, follow‐up and for non‐medical costs.Conclusion In women with gestational hypertension or mild pre‐eclampsia at term, induction of labour is less costly than expectant monitoring because of differences in resource use in the antepartum period. As the trial already demonstrated that induction of labour results in less progression to severe disease without resulting in a higher caesarean section rate, both clinical and economic consequences are in favour of induction of labour in these women.Trial registration The trial has been registered in the clinical trial register as ISRCTN08132825.
- 14 September 2010
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 117 (13) , 1577-1585
An economic analysis of induction of labour and expectant monitoring in women with gestational hypertension or pre‐eclampsia at term (HYPITAT trial)
Please cite this paper as:Vijgen S, Koopmans C, Opmeer B, Groen H, Bijlenga D, Aarnoudse J, Bekedam D, van den Berg P, de Boer K, Burggraaff J, Bloemenkamp K, Drogtrop A, Franx A, de Groot C, Huisjes A, Kwee A, van Loon A, Lub A, Papatsonis D, van der Post J, Roumen F, Scheepers H, Stigter R, Willekes C, Mol B, Van Pampus M for the HYPITAT study group. An economic analysis of induction of labour and expectant monitoring in women with gestational hypertension or pre‐eclampsia at term (HYPITAT trial). BJOG 2010;117:1577–1585.Objective To assess the economic consequences of labour induction compared with expectant monitoring in women with gestational hypertension or pre‐eclampsia at term.Design An economic analysis alongside the Hypertension and Pre‐eclampsia Intervention Trial At Term (HYPITAT).Setting Obstetric departments of six university and 32 teaching and district hospitals in the Netherlands.Population Women diagnosed with gestational hypertension or pre‐eclampsia between 36+0and 41+0 weeks of gestation, randomly allocated to either induction of labour or expectant monitoring.Methods A trial‐based cost‐effectiveness analysis was performed from a societal perspective during a 1‐year time horizon.Main outcome measures One‐year costs were estimated and health outcomes were expressed as the prevalence of poor maternal outcome defined as either maternal complications or progression to severe disease.Results The average costs of induction of labour (n = 377) were €7077 versus €7908 for expectant monitoring (n = 379), with an average difference of −€831 (95% CI −€1561 to −€144). This 11% difference predominantly originated from the antepartum period: per woman costs were €1259 for induction versus €2700 for expectant monitoring. During delivery, more costs were generated following induction (€2190) compared with expectant monitoring (€1210). No substantial differences were found in the postpartum, follow‐up and for non‐medical costs.Conclusion In women with gestational hypertension or mild pre‐eclampsia at term, induction of labour is less costly than expectant monitoring because of differences in resource use in the antepartum period. As the trial already demonstrated that induction of labour results in less progression to severe disease without resulting in a higher caesarean section rate, both clinical and economic consequences are in favour of induction of labour in these women.Trial registration The trial has been registered in the clinical trial register as ISRCTN08132825.
- Open Access
- 9 September 2009
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 9 (1) , 42
Assessment of perinatal outcome after sustained tocolysis in early labour (APOSTEL-II trial)
Preterm labour is the main cause of perinatal morbidity and mortality in the Western world. At present, there is evidence that tocolysis for 48 hours is useful in women with threatened preterm labour at least before 32 weeks. This allows transfer of the patient to a perinatal centre, and maximizes the effect of corticosteroids for improved neonatal survival. It is questionable whether treatment with tocolytics should be maintained after 48 hours.
- 9 September 2009
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 9 (1) , 42
Open AccessAssessment of perinatal outcome after sustained tocolysis in early labour (APOSTEL-II trial)
Preterm labour is the main cause of perinatal morbidity and mortality in the Western world. At present, there is evidence that tocolysis for 48 hours is useful in women with threatened preterm labour at least before 32 weeks. This allows transfer of the patient to a perinatal centre, and maximizes the effect of corticosteroids for improved neonatal survival. It is questionable whether treatment with tocolytics should be maintained after 48 hours.